Brief Summary

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Website: https://clinicaltrials.gov/study/NCT05079282

Sponsors and Collaborators: Ono Pharmaceutical Co. Ltd

Contacts and Locations

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05079282